CDNA - CareDx Inc Stock Price, Fair Value and News

8.07USD-0.24 (-2.89%)Delayed as of 22 Apr 2024, 12:56 pm ET

Market Summary

USD8.07-0.24

Delayedas of 22 Apr 2024, 12:56 pm

-2.89%

CDNA Stock Price

View Fullscreen

CDNA RSI Chart

CDNA Valuation

Market Cap

430.3M

Price/Earnings (Trailing)

-2.26

Price/Sales (Trailing)

1.53

EV/EBITDA

-1.98

Price/Free Cashflow

-23.4

CDNA Price/Sales (Trailing)

CDNA Profitability

Operating Margin

81.58%

EBT Margin

-67.83%

Return on Equity

-72.81%

Return on Assets

-40.76%

Free Cashflow Yield

-4.27%

CDNA Fundamentals

CDNA Revenue

Revenue (TTM)

280.3M

Rev. Growth (Yr)

-20.41%

Rev. Growth (Qtr)

-2.42%

CDNA Earnings

Earnings (TTM)

-190.3M

Earnings Growth (Yr)

-544.32%

Earnings Growth (Qtr)

-402.86%

Breaking Down CDNA Revenue

52 Week Range

8.47

(Low)(High)

Last 7 days

-2.5%

Last 30 days

-17.0%

Last 90 days

-10.0%

Trailing 12 Months

-3.6%

How does CDNA drawdown profile look like?

CDNA Financial Health

Current Ratio

4.02

CDNA Investor Care

Buy Backs (1Y)

3.53%

Diluted EPS (TTM)

-3.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	319.6M	309.3M	297.1M	280.3M
2022	308.4M	314.9M	318.6M	321.8M
2021	221.2M	253.6M	275.8M	296.4M
2020	139.5M	149.8M	169.4M	192.2M
2019	88.5M	102.1M	114.8M	127.1M
2018	50.8M	56.6M	65.6M	76.6M
2017	45.7M	47.0M	46.7M	48.3M
2016	27.5M	31.1M	36.4M	40.6M
2015	28.6M	29.0M	29.4M	28.1M
2014	23.0M	24.4M	25.2M	27.3M
2013	20.9M	21.3M	21.7M	22.1M
2012	0	0	0	20.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of CareDx Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	jain abhishek	sold (taxes)	-2,239	9.53	-235	chief financial officer
Apr 04, 2024	maag peter	acquired	-	-	1,249	-
Apr 04, 2024	goldberg michael	acquired	-	-	3,686	-
Feb 05, 2024	johnson alexander l	sold (taxes)	-9,587	8.56	-1,120	see remarks
Feb 02, 2024	johnson alexander l	sold (taxes)	-36,327	8.72	-4,166	see remarks
Feb 01, 2024	jain abhishek	sold (taxes)	-101,845	8.88	-11,469	chief financial officer
Feb 01, 2024	jain abhishek	acquired	-	-	174,520	chief financial officer
Feb 01, 2024	johnson alexander l	sold (taxes)	-99,855	8.88	-11,245	see remarks
Feb 01, 2024	johnson alexander l	acquired	-	-	174,520	see remarks
Jan 29, 2024	johnson alexander l	sold (taxes)	-11,065	9.88	-1,120	see remarks

Which funds bought or sold CDNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	ARK Investment Management LLC	reduced	-18.5	-24,236,400	62,100,200	0.43%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	10,267	195,460	197,620	-%
Apr 15, 2024	Security National Bank	sold off	-100	-468	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-27.88	-436,387	763,973	0.02%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	-564	4,236	-%
Apr 11, 2024	ARMSTRONG HENRY H ASSOCIATES INC	unchanged	-	-22,610	169,822	0.02%
Apr 05, 2024	GAMMA Investing LLC	added	27.92	768	2,086	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	9.23	-102,496	2,742,880	0.01%
Apr 05, 2024	CWM, LLC	added	2,095	14,000	15,000	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	7,500	18,000	0.01%

Are Funds Buying or Selling CDNA?

Are funds buying CDNA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CDNA

No. of Funds

Unveiling CareDx Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	arrowmark colorado holdings llc	0%	0	SC 13G/A
Feb 13, 2024	bellevue asset management (uk) ltd.	7.3%	3,954,792	SC 13G/A
Feb 13, 2024	gagnon securities llc	4.7%	2,518,484	SC 13G/A
Feb 13, 2024	vanguard group inc	7.62%	4,119,682	SC 13G/A
Feb 12, 2024	nikko asset management americas, inc.	5.31%	2,874,899	SC 13G
Feb 05, 2024	sumitomo mitsui trust holdings, inc.	5.31%	2,874,899	SC 13G
Jan 29, 2024	ark investment management llc	13.30%	7,194,722	SC 13G/A
Jan 24, 2024	blackrock inc.	10.2%	5,543,666	SC 13G/A
Jan 10, 2024	state street corp	5.17%	2,796,267	SC 13G/A
Jul 07, 2023	blackrock inc.	10.1%	5,439,512	SC 13G/A

Recent SEC filings of CareDx Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	8-K	Current Report
Apr 10, 2024	4	Insider Trading
Apr 09, 2024	4/A	Insider Trading
Apr 09, 2024	4/A	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Mar 11, 2024	8-K	Current Report
Mar 01, 2024	POS AM	POS AM
Feb 28, 2024	10-K	Annual Report
Feb 28, 2024	8-K	Current Report

Peers (Alternatives to CareDx Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.2B	23.9B	-6.45%	-5.19%	36.72	7.29	-10.33%	-33.23%
IDXX	39.6B	3.7B	-10.02%	-2.89%	46.84	10.81	8.72%	24.44%
A	38.9B	6.7B	-9.88%	-2.07%	31.47	5.78	-2.81%	-6.58%
DGX	14.2B	9.3B	0.58%	-10.70%	16.65	1.54	-6.38%	-9.73%
CRL	11.6B	4.1B	-15.49%	14.49%	24.52	2.82	3.86%	-2.39%
MEDP	11.4B	1.9B	-6.78%	97.59%	40.46	6.07	29.17%	15.26%
EXAS	11.1B	2.5B	-2.68%	-8.07%	-54.22	4.43	19.93%	67.26%
NTRA	10.3B	1.1B	-8.21%	57.21%	-23.68	9.51	31.99%	20.63%
MID-CAP
NEOG	2.5B	929.2M	-25.64%	-30.20%	1.6K	2.71	28.93%	111.61%
GH	2.0B	563.9M	-10.26%	-34.59%	-4.08	3.47	25.45%	26.76%
SMALL-CAP
CDNA	430.3M	280.3M	-16.97%	-3.59%	-2.26	1.53	-12.89%	-148.37%
ACRS	87.9M	31.2M	5.04%	-86.38%	-0.99	2.81	5.03%	-1.81%
AWH	43.1M	9.2M	0.29%	-35.85%	-2.58	4.71	11.85%	44.12%
APDN	5.8M	9.0M	-32.00%	-67.31%	-0.8	0.64	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

CareDx Inc News

Latest updates

CareDx Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-2.4%	65,569,000	67,192,000	70,301,000	77,262,000	82,384,000	79,359,000	80,634,000	79,416,000	79,220,000	75,589,000	74,188,000	67,400,000	58,644,000	53,369,000	41,801,000	38,380,000	35,821,000	33,811,000	31,454,000	25,982,000	23,509,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15,025,000	12,392,000	12,716,000	11,494,000	11,512,000	9,733,000	10,509,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26,776,000	25,988,000	23,105,000	22,317,000	19,942,000	16,249,000	13,000,000
Operating Expenses	96.1%	188,201,000	95,975,000	97,925,000	101,586,000	101,504,000	96,698,000	102,353,000	98,469,000	94,619,000	84,316,000	78,930,000	68,258,000	61,711,000	56,276,000	52,604,000	44,131,000	51,988,500	40,558,000	26,786,000	21,645,000	45,210,000
S&GA Expenses	8.3%	19,999,000	18,474,000	21,630,000	23,231,000	23,668,000	22,261,000	26,950,000	23,148,000	20,824,000	21,370,000	19,599,000	15,452,000	16,131,000	13,870,000	12,134,000	11,723,000	10,267,000	11,058,000	10,644,000	6,925,000	5,754,000
R&D Expenses	-3.8%	18,276,000	19,000,000	20,233,000	24,357,000	23,570,000	22,306,000	22,632,000	21,880,000	22,046,000	19,439,000	19,036,000	16,004,000	13,325,000	12,474,000	13,129,000	10,013,000	8,946,000	8,521,000	7,630,000	5,614,000	3,782,000
EBITDA Margin	-Infinity%	-0.63	-	-0.23	-0.21	-0.20	-0.20	-0.19	-0.13	-0.08	-0.04	-0.01	-0.03	-0.07	-	-	-	-	-	-	-	-
Income Taxes	306.3%	165,000	-80,000	-68,000	124,000	173,000	267,000	-49,000	-12,000	-894,500	-200,000	-100,000	-263,000	-203,500	-200,000	-300,000	-300,000	-228,500	-900,000	-220,000	-606,000	-336,500
Earnings Before Taxes	-400.5%	-117,932,000	-23,565,000	-25,021,000	-23,625,000	-18,156,000	-16,672,000	-21,746,000	-19,660,000	-17,052,000	-12,059,000	-2,027,000	-950,000	-3,686,000	-3,053,000	-6,888,000	-6,123,000	-4,981,000	-2,762,000	-8,067,000	-8,137,000	-4,094,000
EBT Margin	-123.0%	-0.68	-0.30	-0.27	-0.25	-0.24	-0.24	-0.22	-0.16	-0.11	-0.07	-0.04	-0.07	-	-	-	-	-	-	-	-	-
Net Income	-402.9%	-118,097,000	-23,485,000	-24,953,000	-23,749,000	-18,329,000	-16,939,000	-21,697,000	-19,648,000	-16,151,000	-11,897,000	-1,927,000	-687,000	-3,515,000	-2,818,000	-6,558,000	-5,823,000	-4,777,000	-1,813,000	-7,847,000	-7,531,000	-3,755,000
Net Income Margin	-122.8%	-0.68	-0.30	-0.27	-0.25	-0.24	-0.23	-0.22	-0.16	-0.10	-0.07	-0.04	-0.06	-	-	-	-	-	-	-	-	-
Free Cashflow	17.7%	-8,381,000	-10,179,000	-4,122,000	-2,952,000	3,562,000	-10,702,000	-7,500,000	-25,091,000	543,000	-3,241,000	6,950,000	-34,880,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-6.9%	467	501	515	528	543	545	541	547	567	563	557	541	369	354	345	157	152	145	143	128	131
Current Assets	-9.1%	314	345	361	371	388	388	404	411	433	445	441	439	273	259	252	66.00	72.00	68.00	68.00	78.00	81.00
Cash Equivalents	8.2%	82.00	76.00	88.00	75.00	90.00	83.00	167	172	348	353	336	309	135	214	211	32.00	38.00	41.00	44.00	58.00	65.00
Inventory	8.3%	19.00	18.00	19.00	18.00	19.00	18.00	19.00	18.00	17.00	19.00	15.00	14.00	10.00	10.00	9.00	7.00	6.00	6.00	5.00	5.00	5.00
Net PPE	-	-	-	-	-	-	-	-	-	-	19.00	14.00	11.00	11.00	10.00	7.00	6.00	4.00	4.00	4.00	4.00	4.00
Goodwill	0.3%	40.00	40.00	40.00	40.00	38.00	38.00	37.00	37.00	37.00	26.00	26.00	26.00	24.00	24.00	24.00	24.00	24.00	24.00	23.00	-	-
Liabilities	92.0%	205	107	110	108	112	108	98.00	89.00	101	91.00	78.00	70.00	91.00	85.00	84.00	55.00	53.00	47.00	50.00	32.00	35.00
Current Liabilities	7.4%	78.00	73.00	74.00	72.00	76.00	70.00	78.00	67.00	77.00	70.00	56.00	46.00	69.00	62.00	57.00	28.00	35.00	31.00	29.00	16.00	20.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-33.7%	261	394	405	420	431	437	444	458	466	472	480	472	278	269	261	101	99.00	98.00	93.00	96.00	96.00
Retained Earnings	-27.0%	-678	-534	-509	-484	-460	-441	-424	-402	-383	-367	-355	-353	-352	-349	-346	-339	-333	-329	-327	-319	-311
Additional Paid-In Capital	1.0%	947	937	924	912	899	887	875	865	854	843	838	828	632	622	612	448	438	432	425	420	412
Shares Outstanding	-4.9%	52.00	54.00	54.00	54.00	54.00	53.00	53.00	53.00	52.00	53.00	52.00	51.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	437	-	-	-	1,100	-	-	-	4,600	-	-	-	1,700	-	-	-	1,502	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	17.7%	-8,381	-10,179	-499	671	7,185	-7,079	-3,877	-21,468	4,166	382	9,788	-33,630	7,181	5,207	24,098	-3,055	-1,083	605	3,576	-5,867	1,998
Share Based Compensation	-21.4%	9,961	12,671	12,700	13,754	12,126	11,200	12,593	10,634	9,498	10,638	9,398	6,547	5,977	6,748	6,417	4,259	5,407	5,965	4,992	6,053	2,060
Cashflow From Investing	2861.5%	41,367	-1,498	15,348	-14,771	2,475	-75,735	790	-156,032	-7,782	20,202	16,213	19,079	-90,474	-4,236	-3,980	-1,704	-1,342	-3,515	-17,179	-543	-960
Cashflow From Financing	-107408.0%	-26,877	-25.00	-1,566	-1,138	-2,372	-1,031	-1,997	865	-834	-3,133	381	189,228	3,964	1,224	158,696	-735	82.00	746	-272	-688	37,312
Buy Backs	3090.4%	25,970	814	67.00	690	642	-	-	-	-	-	-	-	-698	-	-	-	-	-	-	-	-

CDNA Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues [Abstract]
Total revenue	$ 280,324	$ 321,793	$ 296,397
Operating expenses:
Research and development	81,866	90,388	76,525
Sales and marketing	83,334	96,027	77,245
General and administrative	117,868	100,397	74,964
Restructuring costs	2,320	0	0
Litigation expense (Note 17)	96,300	0	0
Total operating expenses	483,687	399,024	326,123
Loss from operations	(203,363)	(77,231)	(29,726)
Other income (expense):
Interest income, net	11,867	3,762	160
Change in estimated fair value of common stock warrant liability	10	107	106
Other income (expense), net	1,343	(2,872)	(2,628)
Total other income (expense)	13,220	997	(2,362)
Loss before income taxes	(190,143)	(76,234)	(32,088)
Income tax (expense) benefit	(141)	(379)	1,426
Net loss	$ (190,284)	$ (76,613)	$ (30,662)
Net loss per share (Note 3):
Basic (in dollars per share)	$ (3.54)	$ (1.44)	$ (0.59)
Diluted (in dollars per share)	$ (3.54)	$ (1.44)	$ (0.59)
Weighted-average shares used to compute net loss per share:
Basic (in shares)	53,764,705	53,321,625	52,241,076
Diluted (in shares)	53,764,705	53,321,625	52,241,076
Testing services revenue
Revenues [Abstract]
Total revenue	$ 209,685	$ 263,748	$ 259,285
Operating expenses:
Cost of testing services, product, patient and digital solutions	57,642	72,286	71,251
Product revenue
Revenues [Abstract]
Total revenue	33,517	29,251	26,832
Operating expenses:
Cost of testing services, product, patient and digital solutions	18,379	17,639	18,930
Patient and digital solutions
Revenues [Abstract]
Total revenue	37,122	28,794	10,280
Operating expenses:
Cost of testing services, product, patient and digital solutions	$ 25,978	$ 22,287	$ 7,208

CDNA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 82,197,000	$ 89,921,000
Marketable securities	153,221,000	203,168,000
Accounts receivable	51,061,000	66,312,000
Inventory	19,471,000	19,232,000
Prepaid and other current assets	7,763,000	9,216,000
Total current assets	313,713,000	387,849,000
Property and equipment, net	35,246,000	35,529,000
Operating leases right-of-use assets	29,891,000	34,689,000
Intangible assets, net	45,701,000	43,051,000
Goodwill	40,336,000	37,523,000
Restricted cash	586,000	522,000
Other assets	1,353,000	3,828,000
Total assets	466,826,000	542,991,000
Current liabilities:
Accounts payable	12,872,000	9,942,000
Accrued compensation	19,703,000	16,902,000
Accrued and other liabilities	45,497,000	49,131,000
Total current liabilities	78,072,000	75,975,000
Deferred tax liability	136,000	0
Common stock warrant liability	0	32,000
Deferred payments for intangible assets	2,461,000	2,418,000
Operating lease liability, less current portion	28,278,000	33,406,000
Other liabilities	96,551,000	249,000
Total liabilities	205,498,000	112,080,000
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock: $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock: $0.001 par value; 100,000,000 shares authorized at December 31, 2023 and 2022; 51,503,377 shares issued and outstanding at December 31, 2023; 53,583,301 shares issued and 53,533,250 shares outstanding at December 31, 2022	49,000	52,000
Additional paid-in capital	946,511,000	898,806,000
Accumulated other comprehensive loss	(6,963,000)	(7,503,000)
Accumulated deficit	(678,269,000)	(460,444,000)
Total stockholders’ equity	261,328,000	430,911,000
Total liabilities and stockholders’ equity	$ 466,826,000	$ 542,991,000
Common stock, shares outstanding (in shares)	51,503,377	53,533,250

About CareDx Inc

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CEO	Dr. Reginald Seeto M.D., MBBS
WEBSITE	caredx.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	727

CareDx Inc Frequently Asked Questions

What is the ticker symbol for CareDx Inc? What does CDNA stand for in stocks?

CDNA is the stock ticker symbol of CareDx Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CareDx Inc (CDNA)?

As of Fri Apr 19 2024, market cap of CareDx Inc is 430.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDNA stock?

You can check CDNA's fair value in chart for subscribers.

What is the fair value of CDNA stock?

You can check CDNA's fair value in chart for subscribers. The fair value of CareDx Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CareDx Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CareDx Inc a good stock to buy?

The fair value guage provides a quick view whether CDNA is over valued or under valued. Whether CareDx Inc is cheap or expensive depends on the assumptions which impact CareDx Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDNA.

What is CareDx Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, CDNA's PE ratio (Price to Earnings) is -2.26 and Price to Sales (PS) ratio is 1.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDNA PE ratio will change depending on the future growth rate expectations of investors.